Company profile

Neurim Pharmaceuticals Ltd.

Privately held: no public share price · Israel

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Melatonin prolonged-release(Circadin)No recent activity
Phase 3
Undisclosed / early pipeline
Indication not yet linked
Piromelatine
Phase 3
MT1/MT2/5-HT1A/1D receptorsSmall molecule
Alzheimer's Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.